Topical Rifamycin SV for Wound Healing After Sapphire FUE Hair Transplantation
Summary
This prospective, parallel-group controlled clinical study evaluated whether a single topical rifamycin SV protocol added to standardized care after sapphire follicular unit extraction (FUE) was associated with earlier recorded wound healing. One hundred candidates were assessed, and 70 men were individually allocated 1:1 using MedCalc. Five participants were excluded after allocation but before surgery and before receiving the assigned intervention because final preoperative serological testing met prespecified exclusion criteria. The analyzed sample comprised 34 participants in the rifamycin SV group and 31 in the control group. Healing was assessed through postoperative Day 14 using scheduled clinical review and serial photographs. Infection and hypersensitivity were monitored as safety outcomes.
Timeline
- Start
- 2021-12-02
- Primary completion
- 2022-05-15
- Completion
- 2022-06-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifamycin SV | Unknown | 125 mg | Topical |
| Background | Povidone-Iodine | Other / unclassified | 50 ml | Topical |